Medicus Pharma (NASDAQ:MDCX) Coverage Initiated by Analysts at D. Boral Capital

D. Boral Capital assumed coverage on shares of Medicus Pharma (NASDAQ:MDCX) in a report published on Monday,Benzinga reports. The brokerage issued a buy rating and a $14.00 price objective on the stock.

Other equities analysts have also issued research reports about the stock. Maxim Group initiated coverage on shares of Medicus Pharma in a research report on Tuesday, December 17th. They set a “buy” rating and a $10.00 target price for the company. Brookline Capital Management raised shares of Medicus Pharma to a “strong-buy” rating in a report on Monday, December 23rd.

Medicus Pharma Stock Performance

MDCX stock opened at $3.61 on Monday. The company’s 50-day moving average is $3.46. Medicus Pharma has a twelve month low of $1.80 and a twelve month high of $6.00.

Medicus Pharma (NASDAQ:MDCX) last issued its quarterly earnings results on Friday, March 28th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.14. As a group, equities analysts forecast that Medicus Pharma will post -1.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Medicus Pharma

An institutional investor recently bought a new position in Medicus Pharma stock. Interchange Capital Partners LLC purchased a new position in Medicus Pharma Ltd. (NASDAQ:MDCX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 1,457,165 shares of the company’s stock, valued at approximately $3,628,000. Medicus Pharma makes up 1.3% of Interchange Capital Partners LLC’s portfolio, making the stock its 15th largest position. Interchange Capital Partners LLC owned approximately 13.43% of Medicus Pharma as of its most recent SEC filing.

Medicus Pharma Company Profile

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.